Phaseline

Targets › FOXP3

FOXP3 (Forkhead box protein P3): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.

Transcriptional regulator which is crucial for the development and inhibitory function of regulatory T-cells (Treg). Plays an essential role in maintaining homeostasis of the immune system by allowing the acquisition of full suppressive function and stability of the Treg lineage, and by directly modulating the expansion and function of conventional T-cells. (UniProt, Q9BZS1)

Open in Phaseline: the race on FOXP3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rafael Correa-RochaAutologous thyTreg
Regulatory T cells differentiated from thymic tissue, expanded and stimulated with IL-2
FOXP3Phase 1Heart TransplantationDec 2026

Conditions

Heart Transplantation (1)

Modalities

other (1)

Companies

Rafael Correa-Rocha (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.